Please login to the form below

07 Good Pharma

Better for patients, better for business

Pharma is a dirty word to some. Even to those with milder views, it’s an industry often painted with an unenviable public image. Negative portrayals of massive conglomerates that happily trade patient wellbeing for profits are too frequently projected upon the pharmaceutical sector from those outside of it. Indisputably, pharma companies are powered by profit, but so is any business. Revenue pays salaries and overheads. It’s the lifeblood of any company, big or small. Why then, does pharma get such a bad rep?

Because it matters. Because we are an ageing population terrified by the concept of growing old. Because we are more aware of our lifestyle choices, more informed about serious illness and more concerned about what it means to us. Healthcare is vital to protecting that most sacred of human commodities; our lives. It’s a big responsibility and so it’s perhaps natural that, as a wider society, we’re critical of those charged with looking after us.

So who should run pharma - shareholders or stakeholders? Both. At Havas Lynx we are passionate about improving patients’ lives and we know that the pharmaceutical companies we work with share this commitment. We believe that the key to long-term success is finding a balance between making money and making a difference. By combining moral and commercial drivers, companies can breed a long-term financial security that allows continued investment in life-changing innovations.

30th January 2014

Share

Tags

Company Details

Havas Lynx Group

+44 (0)161 228 7756

Contact Website

Address:
52 Princess Street
Manchester
M1 6JX

Latest content on this profile

Patient Centricity On Trial
Today, 40 million patients are needed for over 300,00 clinical trials, worldwide. This year’s white paper explores how bringing the patient experience front and centre in clinical trials could revolutionise trial design, retention and recruitment – ultimately improving outcomes.
Havas Lynx Group
Havas Lynx Group launches white paper on Clinical Trials Day to address $40bn clinical trials challenge
Patient centricity is a misused buzzword to signpost all manner of token efforts, but the real winners will be those who embrace it throughout their organisation. Not just because it’s the right thing to do, but because it is the only way to fix a broken model.
Havas Lynx Group
19 Patient Centricity on Trial
Clinical trials are broken and only patients can help us fix them. If we let them.
Havas Lynx Group
15 Personalized Medicine: It's Time To Get Creative

Havas Lynx Group
14 Interpreting the Future of Healthcare

Havas Lynx Group
04 A Healthy Ambience
Creating a Lifeline to the New Digital User
Havas Lynx Group